Absence of Mir-142 Mutation in Chinese Patients with Acute Myeloid Leukemia

Fei-Fei Chen,Yin-Jun Lou,Jian Chen,Jing Jin,Jia-Ni Zhou,Xiu-Feng Yin,Zhi-Juan Zhu,Chao Hu,Meng-Xia Yu,Huan-Ping Wang,Jie Jin

DOI: https://doi.org/10.3109/10428194.2014.907892

2014-01-01

Leukemia & Lymphoma

Abstract:Recently, Ley and his colleagues reported a 4/200 (2.0%) mutation rate of miR-142 in patients with acute myeloid leukemia (AML). All four of these patients had one mutation site located in the seed region of miR-142-3p, which may aff ect the message RNA of its target genes [1]. MicroRNAs are a class of small non-coding RNAs that negatively regulate gene expression at the post-transcriptional level. miR-142 is a hematopoietic specifi c microRNA [2]. Th e validated targets of miR-142-3p include CD133, ADCY9, interleukin-6 (IL-6) and RAC1 [3 – 6]. BTG3 is a validated target of miR-142-5p [7]. Previously, Kwanhian and his colleagues found that miR-142 was mutated in 20% of patients diagnosed with diff use large B-cell lymphoma [8]. Moreover, aberrant expression of miR-142-5p and miR-142-3p has been observed in gastric mucosa-associated lymphoid tissue lymphoma and T-cell lymphoblastic leukemia, respectively [9,10]. Recent evidence suggests that low expression of miR-142 is involved in the development of AML. Patients with de novo AML show decreased expression of miR-142-3p [11]. High expression of miR-142 is associated with better overall survival in the intermediate cytogenetic risk group [12]. Nowadays, it has become more important to analyze the prognostic infl uence of mutations in groups of patients who have been treated similarly, such as patients who have participated in a clinical trial. Th e use of multivariate analysis has been recommended to explore the impact of a specifi c gene combined with other mutant genes and also within diff erent risk subgroups. Based on this suggestion, we analyzed the mutation status of miR-142 in 183 patients with de novo AML who participated in a phase 3 Chinese AML clinical trial (ChiCTR-TRC-06000054) [13]. Informed consent was obtained from all patients. Th e characteristics of these patients are listed in Table I. Th ere was no sample selection bias, as the distribution of patients ’ age, sex, French – American – British (FAB) subtype, cytogenetic profi le and mutation status in this study was comparable to that reported in our previous phase 3 Chinese AML clinical trial [13]. Total DNA was extracted from bone marrow mononuclear cells after Ficoll gradient centrifugation in 101 patients, using methanol – acetic acid-fi xed cells that had been prepared for cytogenetic analysis in 26 patients, and archived bone marrow slides in another 56 patients. miR-142 was amplifi ed by polymerase chain reaction (PCR) using the forward primer: 5 ′ -CATGCTGAGTCACCGCCCAC-3 ′ and reverse primer: 5 ′ TTCCCCTCCACGTACCATCCCT-3 ′ . Mutation was detected by direct Sanger sequencing of PCR products. In our study, we did not fi nd any miR-142 mutations in 183 patients with de novo AML. Th e mutation rate of other genes studied was similar between samples obtained from archived bone marrow slides and the other two resources (DNA extracted from bone marrow mononuclear cells after Table I. Characteristics of 183 patients. Characteristic Value Median age at diagnosis (range; years) 38 (14 – 59) Males, no. (%) 93 (50.1) Median bone marrow blasts (range; %) 67 (20 – 98) Median white cell count at diagnosis (range, 10 9 /L) 19.5 (1.0 – 487)